Goran Dahl

Göran Dahl is a senior scientist at AstraZeneca's BioPharmaceuticals R&D site in Gothenburg, Sweden, where he is based in the Protein Sciences, Structural Biology, and Biophysics group within Discovery Sciences. He holds a PhD in Biochemistry from Uppsala University (2005-2009) and has worked in the drug discovery industry for over 15 years. His research centres on the biophysical characterisation of drug-target interactions, with expertise in surface plasmon resonance (SPR), mass photometry (MP), dynamic scanning fluorimetry (DSF), isothermal calorimetry (ITC) and Spectral Shift (SpS) to support small molecule drug discovery programmes — from fragment screening all the way to clinical candidate selection. Göran has contributed to a broad range of therapeutic areas at AstraZeneca and has co-authored many scientific publications, ranging from PROTAC characterization and safety, to binding kinetic – pharmacokinetic relationships.